Literature DB >> 6786826

Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?

M Schmidt-Gollwitzer, W Hardt, K Schmidt-Gollwitzer, M von der Ohe, J Nevinny-Stickel.   

Abstract

The long-acting stimulatory luteinizing hormone - releasing hormone analogue D-Ser(TBU)6-EA10-LH-RH (buserelin) was administered intranasally once daily in a dose of 400 mcg to 24 normally ovulating women and to 4 women with pre-existing endocrine dysregulation. Ovulation was inhibited in 136 out of 156 treatment months. In 20 treatment months, progesterone values temporarily increased indicating luteinization of follicles or ovulation with defective corpus luteum function. Estradiol secretion showed a tendency to lower values as treatment progressed but individually indicated follicle maturation until the end of the observed medication period. Bleeding pattern ranged from menses-like bleeding in regular as well as irregular intervals to amenorrhea. The morphological findings of 31 endometrial biopsies of 20 volunteers ranged from atrophy (n = 4) to proliferation (n = 25) with early signs of hyperplasia as well as early secretory transformation (n = 2). The morphological alterations indicate that unopposed estrogen stimulation of the endometrium is the main problem of long-term contraception with the dose schedule of buserelin used.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6786826     DOI: 10.1016/0010-7824(81)90104-9

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin.

Authors:  C Larsen; M Niebuhr Jørgensen; B Tommerup; N Mygind; E E Dagrosa; H G Grigoleit; V Malerczyk
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  GnRH and its analogues. Current therapeutic applications and new prospects.

Authors:  H M Fraser
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

4.  Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.

Authors:  J G Klijn; F H de Jong; M A Blankenstein; R Docter; J Alexieva-Figusch; J Blonk-van der Wijst; S W Lamberts
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 5.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

6.  Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.

Authors:  R W Shaw; H M Fraser; H Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

Review 7.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.